FDA/CDC

FDA alerts doctors to stop administering compounded products


 

The Food and Drug Administration today alerted physicians to stop administering or providing drugs manufactured by Cantrell Drug, including opioid products and other drugs intended for sterile injection, because the company has failed to ensure quality and sterility in its compounding operations, which could seriously compromise patient safety.

Health care providers should check medical supplies and separate anything produced by Cantrell Drug, which can be identified by finding the company’s name on the label. The FDA also recommended that physicians seek alternative arrangements for medicines and that any patients who have any products made by Cantrell contact their physicians.

FDA icon
The FDA has sought legal action against Cantrell to halt its production and distribution operations. The FDA raised serious concerns after an inspection in June 2017 revealed unsanitary conditions and violations of current Good Manufacturing Practice. This led to a recall and cessation of production of all sterile products; however, Cantrell resumed production and distribution against FDA advice.

So far, the FDA is not aware of any illness or injuries caused by potentially contaminated products from Cantrell, but any that do arise should be reported to the FDA’s MedWatch program.

Read more about this alert in the FDA website.

Recommended Reading

VIDEO: How to manage surgical pain in opioid addiction treatment
MDedge Neurology
In close vote, advisory panel prefers Shingrix over Zostavax
MDedge Neurology
Eliminating patient-controlled analgesia accelerates discharge after bariatric surgery
MDedge Neurology
Conference News Roundup—American Society of Anesthesiologists
MDedge Neurology
Fremanezumab may reduce chronic migraine frequency
MDedge Neurology
New buprenorphine formulation approved for medication-assisted treatment
MDedge Neurology
Novel herpes zoster vaccine is more cost effective than old vaccine
MDedge Neurology
Persistent opioid use a risk after surgery in teens and young adults
MDedge Neurology
Serotonin syndrome warnings magnify its rare probability
MDedge Neurology
Serotonin syndrome risk with triptans and antidepressants ‘very low’
MDedge Neurology